All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Jason Westin, MD Anderson Cancer Center, Houston, US. We asked, How do you approach the treatment of untreated diffuse large B-cell lymphoma (DLBCL)?
How do you approach the treatment of untreated DLBCL?
Westin begins by highlighting the advantages of the international prognostic index but finds that it does not aid in selecting treatment for patients ineligible for R-CHOP. Westin outlines situations in which he would deviate from R-CHOP, including high international prognostic index and certain disease subtypes. He discusses future treatments such as circulating tumor DNA and the POLARIX trial investigating Pola-R-CHP. Finally, he predicts that in the future disease definitions of subtype, in terms of response to therapy, will need to improve.
ICML 2019 | Practice-changing abstracts
Practice-changing abstracts presented during the ICML 2019 conference.
ICML 2019 | Overview of the phase II SMART START trial
The Lymphoma Hub were pleased to speak to Dr. Jason Westin, MD Anderson Cancer Center, Texas, US about the phase II SMART SMART trial of rituximab, lenalidomide, and ibrutinib alone prior to...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox